title: Donor treatment with phentolamine mesylate improves machine preservation dynamics and early renal allograft function.
abstract: BACKGROUND
  It has been suggested that pharmacologic conditioning of the donor before organ procurement may protect the renal allograft from injuries associated with the cold ischemic period. We compared the administration of two vasoactive agents before organ procurement to: (1) determine their influence on machine perfusion characteristics and (2) determine their impact on delayed graft function (DGF) in transplanted renal allografts.
  
  
  METHODS
  Between January 1997 and December 1998, 150 kidneys were procured from heart-beating donors and preserved in our laboratory by machine perfusion (MP) or cold storage (CS). The following vasoactive agents were randomly administered to the donor 5 min before aortic cross clamp: phentolamine mesylate (PM) or hydralazine (H). The control groups received no donor conditioning. Kidneys were grouped as follows: (1) MP+PM, (2) MP+H, (3) MP, (4) CS+PM, (5) CS+H, (6) CS. 10 mg PM/50 kg donor weight was administered to the PM groups and 20 mg H/50 kg donor weight was administered to the H groups. DGF was defined as the need for dialysis within the first 7 days after the transplant.
  
  
  RESULTS
  MP+PM increased renal flow by 12% and decreased renal resistance by 18% compared with the MP+H group, and increased renal flow by 23% and decreased renal resistance by 30% compared with the MP group. Moreover, the MP+PM group was associated with improved early allograft function.
  
  
  CONCLUSIONS
  Donor treatment with PM immediately before aortic cross-clamp is associated with improved machine perfusion dynamics (renal flow and renal resistance) and lower incidence of DGF compared with donor treatment with H or no treatment. Moreover, MP of renal allografts was associated with improved early function compared with CS grafts.
authors.affiliation: Organ Preservation Unit, Center for Organ Preservation and Transplantation Research, The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Polyak
authors.forename: B O
authors.initials: BO
authors.lastname: Arrington
authors.forename: S
authors.initials: S
authors.lastname: Kapur
authors.forename: W T
authors.initials: WT
authors.lastname: Stubenbord
authors.forename: M
authors.initials: M
authors.lastname: Kinkhabwala
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology*; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D016030:Kidney Transplantation; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D010477:Perfusion / Q000295:instrumentation; D010646:Phentolamine / Q000494:pharmacology*; D012079:Renal Circulation / Q000187:drug effects; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D006830:Hydralazine; D010646:Phentolamine